Cancer (e.g., liver cancer)

Mechanism of Action

Has multiple working mechanisms, including inhibiting the growth of cancer cells, inhibiting the angiogenesis of cancer cells, and inhibiting the metastasis of cancer cells.

Current Status
  1. Pre-clinical studies were proceeded in accordance with international R&D standards for botanical new drugs (e.g., the corresponding standards published by ICH and the US FDA). All the established techniques and quality met international standards. The anti-cancer activity of the drug has been verified with various cancer cells, and the safety range of the drug has been evaluated by comparing its toxicological study results with those in normal cells and animal studies. The anti-cancer activity of the Antrodia cinnamomea-based new drug has been validated in different in vivo disease models.
  2. Greenlighted by the US FDA and TFDA (the Food and Drug Administration, Ministry of Health and Welfare of Taiwan) to proceed with the phase 1 clinical trial. The phase 1 clinical trial in Taiwan started in 2020.
Product Advantages
  1. Safety: 100 times inhibition of cancer cells than in normal cells (in terms of concentration) and therefore has high selectivity
  2. Effectiveness: Inhibit the growth of a subcutaneously or orthotopically transplanted malignant cancer significantly
  3. Quality assurance: To ensure batch-to-batch consistency of the drug, a proper quality control process has been established for the entire manufacturing process from the raw materials to the finished product.
  4. Monopoly: Oneness Biotech has been granted with patents in many countries for the anti-cancer active components, the drug manufacturing process, and the use of the drug. The patent protection of the product lasts at least till 2035.
Market Potentials

Millions of patients with liver cancer die each year. Hepatocellular carcinoma (HCC) is the most common primary liver cancer and makes up about 90% of all liver cancer cases. As currently available treatment solutions contribute to only a limited increase in the overall survival rate, a new therapy is needed to meet the medical needs in HCC. It is estimated that the market size of liver cancer treatment in 2025 is about USD 5 billion. (Reference: Nature review)

R&D Progress
In Progress
Research Code Therapeutic Area Indication Pre-Clinical Phase I Phase II Phase III NDA Market More
  • OB318
    Cancer (e.g., liver cancer)

    OB318 is a new drug for hepatocellular carcinoma (HCC) which is the most common type of liver cancers, accounting for 90% of the cases



要下載瀏覽器,請直接點擊以下: IE瀏覽器現已不支援大多數網站,並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

  1. 開啟新分頁(紅色框)
  2. 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
  3. 點擊【立即啟動】(藍框處)打開 Microsoft Edge
    啟動Microsoft Edge